Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Egis Pharmaceuticals PLC

www.egis.hu

Latest From HistoSonics Inc.

J&J Announces New Device Collaborations

The Johnson & Johnson Innovation Center projects include a focus on solid-tumor resections, knee replacement procedures and atrial fibrillation ablation – as well as tracking down biomarkers tied to diabetes and prostate cancer.

Medical Device

Advancing Ablative Tumor Therapies Into Primary Treatments

For many cancers, there is a need for a third option between the two current choices of radical tissue destruction and watchful waiting. New cancer ablation devices in development have the potential to fill that gap. Ablative tumor therapies can play a role in eradication of early-stage and localized tumors, as salvage therapies in patients who've failed other therapies, and for patients whose health precludes surgery or further radiation. Ablation has many advantages. It's a cost-effective and minimally invasive alternative to robotic surgery or radiation devices, and may lead to fewer side effects and complications than current primary tumor treatments. But proving that ablation can save lives compared to more radical forms of therapy requires clinical evidence from multiyear outcome trials that few smaller companies are willing to invest in. There's little evidence to date that venture investors will see returns. But the race is on among companies hoping to become the first device approved for low-risk, localized prostate cancer, a potentially game-changing event.
Medical Device

HistoSonics Inc.

Men who suffer from benign prostatic hyperplasia could soon have an alternative to surgery, if all goes well for HistoSonics Inc. The company is developing the Histotripsy system, an image-guided, robotic-manipulated procedure that uses ultrasound to excise and mechanically homogenize tissue without heat. HistoSonics believes its noninvasive office-based treatment option will be fast, effective, and cause fewer adverse effects than existing BPH treatments.
Medical Device

Start-Up News

Noteworthy news from medtech start-ups. This month we profile EndoControl, HistoSonics, Neuravi and Virtual Incision.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Hungary
  • Parent & Subsidiaries
  • Egis Pharmaceuticals PLC
  • Senior Management
  • István OrbánHodász, Pres.
  • Contact Info
  • Egis Pharmaceuticals PLC
    Phone: (36) 803 5555
    Keresztúri út 30-38
    Budapest, 1106
    Hungary
Advertisement
Advertisement
UsernamePublicRestriction

Register